We are excited to announce the expansion of our collaboration with BostonGene. BostonGene is a leading provider of AI-driven molecular and immune profiling solutions. FibroFighters began working with this innovative company about a year and half ago. From the start, BostonGene has been incredibly receptive to our patient’s needs by formulating programs geared towards our rare cancer. This expansion continues to strengthen our position with several key CLIA labs to expand existing projects. 

This expansion of our collaboration with BostonGene, along with our recently announced partnership with Pangea Biomed, are key to the goal of FibroFighters Foundation to support all patients to find the best treatments for our rare cancer. We appreciate and thank the FLC patients and their caregivers who helped refer us to some of these key partners.  We truly are “Slaying the Fibrolamellar Beast Together.”

Read the press release here: https://bostongene.com/?press=bostongene-and-fibrofighters-collaborate-to-revolutionize-clinical-care-for-patients-with-fibrolamellar-carcinomas&mkt_tok=OTM3LUJZTS01NDcAAAGPBepTVXqwrVZRs0_nc2CyxScWGpl19N0ageLvF41HnztCCoWQTz0Wiu4JYzolEJzh1rjOaFbSn0py8nWReA